市場調查報告書

突破治療指定市場:各用途、終端用戶、地區,市場分析,規模,佔有率,趨勢,及預測(2021年∼2027年)

Breakthrough Therapy Designations Market, By Application, By End-User, and By Geography - Analysis, Size, Share, Trends, & Forecast from 2021-2027

出版商 AnalystView Market Insights 商品編碼 950974
出版日期 內容資訊 英文 209 Pages
商品交期: 2-3個工作天內
價格
突破治療指定市場:各用途、終端用戶、地區,市場分析,規模,佔有率,趨勢,及預測(2021年∼2027年) Breakthrough Therapy Designations Market, By Application, By End-User, and By Geography - Analysis, Size, Share, Trends, & Forecast from 2021-2027
出版日期: 2020年07月01日內容資訊: 英文 209 Pages
簡介

全球突破治療指定市場,至2019年為684億美金。該市場預計在在預測期間內(2021年∼2027年)以15.3%的年複合成長率成長。該市場的主要成長要素,是獲得BT狀態的藥物數增加,和對治療罕見疾病和癌症治療的藥物需求增加。再加上新興國家的醫療保健支出增加和智慧財產權(IP)法的改善,在預測期間內推動產業成長。但,由於對學名藥的偏好擴展預計是同市場課題。

本報告提供全球突破治療指定市場的相關調查,市場機會和趨勢,成長及阻礙因素,各用途、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 市場概要

第2章 摘要整理

  • 市場明細
    • 各用途
    • 各終端用戶
    • 各地區
  • 競爭考察

第3章 市場趨勢

  • 市場成長要素
  • 阻礙市場要素
  • 市場機會
  • 市場未來趨勢

第4章 產業調查

  • 波特的五力分析
  • 行銷策略分析
  • 成長預測製圖
  • 法規組成架構分析

第5章 COVID-19的影響分析

  • COVID-19大流行疫情前的影響分析
  • COVID-19大流行疫情後的影響分析

第6章 市場形勢

  • 市場佔有率分析
  • 主要的創新者
  • 各主要製造商的明細資料
    • 現有企業分析
    • 新興企業分析

第7章 市場分析:各用途

  • 概況
  • 腫瘤
  • 感染疾病
  • 稀少疾病
  • 自體免疫疾病
  • 肺部疾病
  • 神經病變
  • 其他

第8章 市場分析:各終端用戶

  • 概況
  • 醫院
  • 診療所
  • 研究機關
  • 研究所

第9章 市場分析:各地區

  • 簡介
    • 市場區隔佔有率分析(2020 & 2027)
  • 北美
  • 歐洲
  • 亞太地區(APAC)
  • 南美
  • 中東、非洲

第10章 供應商分析

  • AbbVie, Inc.
  • Acadia
  • Amgen, Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Eli, Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead
  • GlaxoSmithKline plc
  • Janssen Global Services
  • Novartis AG
  • Pfizer
  • Pharmaceuticals, Inc.
  • Regeneron
  • Sanofi

第11章 分析師的見解

第12章 附錄

目錄

Title:
Breakthrough Therapy Designations Market, By Application (Rare Disease, Oncology, Infectious Disease, Autoimmune Disease, Neurological Disorder, and Pulmonary Disease), By End-User (Clinic, Research Institute, Hospital, and Laboratories), and By Geography (EU, NA, APAC, LATAM, and MEA) - Analysis, Size, Share, Trends, & Forecast from 2021-2027.

REPORT HIGHLIGHT

The global breakthrough therapy designations market was valued at USD 68.4 billion by 2019, growing with 15.3% CAGR during the forecast period, 2021-2027.

Breakthrough therapy designation is a process that accelerates the development and review of drugs, which are intended to treat a serious condition such as cancer, and respiratory infections due to coronavirus. For instance, the BBC recently published a study conducted by Oxford University in cooperation with many hospitals in the UK along with the agreement of numerous patients and their families. The study involved dexamethasone as a part of "Recovery - Randomized Evaluation of COVID-19 Therapy", to cure patients under clinical trials. This trial was set up in nine days and involved 11,500 COVID recruited patients in 175 hospitals across the UK.

According to the Food and Drug Administration, BT also offers indications in the preliminary clinical evidence demonstrating the significant improvement of drugs over available therapy on a clinically significant endpoint(s). The drug approval process, under BT designations, includes the drug review evaluation that is reviewed by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). On average, CDER receives approximately 100 requests per year, whereas CBER receives 15-30 requests per year.

MARKET DYNAMICS

Elevating count of drugs gaining BT status coupled with the rising demand for drugs curing rare diseases and cancer therapies are boosting the industrial growth. For instance, CDER Breakthrough Designation included a count of 156 approvals in 2019. Among these, the approval of Fam-Trastuzumab Deruxtecan-Nxki by Daiichi Sankyo is the latest. The global breakthrough therapy designation market dynamics are also affected directly due to the COVID pandemic, owing to the expedited approval process adopted in developed countries for the discovery of a cure for COVID patients. For instance, the European government-funded National Health Service (NHS) authorized to use steroid dexamethasone; as the world's first coronavirus treatment in June 2020. The study proved effective in reducing the risk of death among severely ill patients.

Moreover, the increasing healthcare expenditure in emerging nations coupled with the improvement in Intellectual Property (IP) laws is also expected to propel the industrial growth during the forecast years. On the contrary, global breakthrough therapy designation market challenges include the expensive nature of breakdown therapy coupled with the diverging preference to generic medicines.

APPLICATION TAKEAWA

Based on the application, this industry is bifurcated into the rare disease, oncology, infectious disease, autoimmune disease, pulmonary disease, neurological disorder, and other diseases. Among these, the infectious disease segment is dominating the global breakthrough therapy designation market growth and is projected to continue at the same pace throughout the forecast years. This dominance is attributed to a surge in the count of anti-infective drugs gaining BT status all across the globe. As per Friends of Cancer Research, Exebacase, sponsored by ContraFect Corporation, was the latest agent that awaits FDA approval, after assigning a BT Designation Disclosure date of Feb. 24th, 2020. The agent treats infectious disease indicating the patients with MRSA bacteremia, including right-sided endocarditis.

Besides, the oncology and rare disease segment are also expected to have significant growth during the upcoming years, owing to the sudden outbreak of the COVID pandemic and the growing awareness about orphan drugs among the consumers. An article published by an online newsletter "ecancer", in May 2020, stated that the people with cancer are highly mortal from COVID-19, as per the healthcare scientists of Montefiore Health System and Albert Einstein College of Medicine. However, the high cost of the drugs approved through BT designation serves to be the global breakthrough therapy designation market restraint, hampering the overall growth.

End-User Takeaway

By end-users, the industry is categorized into hospitals, clinics, research institutes, and laboratories. The research institute segment holds a significant share, followed by hospitals and laboratories. Global breakthrough therapy designation market size is expected to grow in the near future, owing to the shorter approval time for the latest innovative drugs and better product image. Also, the prevalence of chronic disease and the sudden outbreak of coronavirus are also responsible for fueling the growth of this industry.

REGIONAL TAKEAWA

Regionally, the overall market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the majority of share followed by Europe, owing to the shifting preference of patients and healthcare professionals for innovative medicines along with the better intellectual property laws in this region. Other factors such as the increasing disposable income, improving healthcare infrastructure, and the emergence of COVID-19 are supporting the market growth.

Moreover, the Asia Pacific and Latin American industry is expected to offer lucrative growth over the next few years. The development of favorable IP laws in emerging countries like India and China is responsible for positively affecting the overall growth. For instance, the updated data revealed by the World Intellectual Property Organization concluded a total growth rate of 43.66% and 62.66% for patents and trademarks respectively in India only. On the other hand, the growing demand for generic products is however likely to hamper the growth of the market.

COVID-19 IMPACT

The market is also impacted due to the COVID-19 outbreak. This has accelerated the demand for a drug that is effective in curing this deadly disease. The studies have also revealed that the development time through BT therapy is 30% to 50% less as compared to those without designation. This significant reduction in time consumed for the drug development process also plays an essential role in boosting the global breakthrough therapy designation market potential worldwide.

KEY VENDOR TAKEAWA

The leading players of the global breakthrough therapy designations market include Acadia, Amgen, Inc., Boehringer Ingelheim, AstraZeneca, AbbVie, Inc., Eli, Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Gilead, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Janssen Global Services, Pfizer, Pharmaceuticals, Inc., Sanofi, and Regeneron.

Due to the current pandemic condition worldwide, numerous companies are actively involved in new product development along with the innovation of a novel drug that is capable of curing COVID. Apart from this, numerous companies have received FDA approval under CDER Breakthrough Therapy to cure other conditions as well. Such developments account for the approval of IPILIMUMAB and NIVOLUMAB (established names) by Bristol-Myers Squibb Company in March 2020. IPILIMUMAB and NIVOLUMAB both in combination with Nivolumab can be used for the treatment of patients with hepatocellular carcinoma (HCC).

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2016 to 2018

Base Year - 2019

Estimated Year - 2020

Projected Year - 2021 to 2027

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BREAKTHROUGH THERAPY DESIGNATIONS MARKET KEY PLAYERS

AbbVie, Inc.

Acadia

Amgen, Inc.

AstraZeneca

Boehringer Ingelheim

Bristol-Myers Squibb Company

Eli, Lilly and Company

Hoffmann-La Roche Ltd

Gilead Sciences

GlaxoSmithKline plc

Janssen Global Services

Novartis AG

Pfizer, Inc.

Pharmaceuticals, Inc.

Regeneron

Sanofi S.A.

GLOBAL BREAKTHROUGH THERAPY DESIGNATIONS MARKET, BY APPLICATION

Infectious Disease

Rare Disease

Neurological Disorder

Oncology

Other Disease

GLOBAL BREAKTHROUGH THERAPY DESIGNATIONS MARKET, BY END-USER

Clinic

Research Institute

Hospital

Laboratories

GLOBAL BREAKTHROUGH THERAPY DESIGNATIONS MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

The Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

TABLE OF CONTENT

1. BREAKTHROUGH THERAPY DESIGNATION MARKET OVERVIEW

  • 1.1. Study Scope

2. EXECUTIVE SUMMARY

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Application
    • 2.1.2. Market Snippet by End-User
    • 2.1.3. Market Snippet by Region
  • 2.2. Competitive Insights

3. BREAKTHROUGH THERAPY DESIGNATION KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. BREAKTHROUGH THERAPY DESIGNATION INDUSTRY STUDY

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. BREAKTHROUGH THERAPY DESIGNATION MARKET: COVID-19 IMPACT ANALYSIS

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. BREAKTHROUGH THERAPY DESIGNATION MARKET LANDSCAPE

  • 6.1. Market Share Analysis
  • 6.2. Key Innovators
  • 6.3. Breakdown Data, by Key manufacturer
    • 6.3.1. Established Player Analysis
    • 6.3.2. Emerging Player Analysis

7. BREAKTHROUGH THERAPY DESIGNATION MARKET - BY APPLICATION

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Application, 2020 & 2027 (%)
  • 7.2. Oncology
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 7.3. Infectious Disease
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 7.4. Rare Disease
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 7.5. Autoimmune Disease
    • 7.5.1. Overview
    • 7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 7.6. Pulmonary Disease
    • 7.6.1. Overview
    • 7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 7.7. Neurological Disorder
    • 7.7.1. Overview
  • 7.8. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 7.9. Other Disease
    • 7.9.1. Overview
    • 7.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)

8. BREAKTHROUGH THERAPY DESIGNATION MARKET - BY END-USER

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End-User, 2020 & 2027 (%)
  • 8.2. Hospital
    • 8.2.1. Overview
    • 8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 8.3. Clinic
    • 8.3.1. Overview
    • 8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 8.4. Research Institute
    • 8.4.1. Overview
    • 8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 8.5. Laboratories
    • 8.5.1. Overview
    • 8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)

9. BREAKTHROUGH THERAPY DESIGNATION MARKET- BY GEOGRAPHY

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Region, 2020 & 2027 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 9.2.6. The U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.3.10. Rest of Europe
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.4.10. Rest of APAC
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.5.9. Rest of LATAM
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Applications, 2016 - 2027 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)

10. KEY VENDOR ANALYSIS

  • 10.1. AbbVie, Inc.
    • 10.1.1. Company Snapshot
    • 10.1.2. Financial Performance
    • 10.1.3. Types Benchmarking
    • 10.1.4. Strategic Initiatives
  • 10.2. Acadia
  • 10.3. Amgen, Inc.
  • 10.4. AstraZeneca
  • 10.5. Boehringer Ingelheim
  • 10.6. Bristol-Myers Squibb Company
  • 10.7. Eli, Lilly and Company
  • 10.8. F. Hoffmann-La Roche Ltd
  • 10.9. Gilead
  • 10.10. GlaxoSmithKline plc
  • 10.11. Janssen Global Services
  • 10.12. Novartis AG
  • 10.13. Pfizer
  • 10.14. Pharmaceuticals, Inc.
  • 10.15. Regeneron
  • 10.16. Sanofi

11. 360 DEGREE ANALYSTVIEW

12. APPENDIX

  • 12.1. Assumption and Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Breakthrough therapy designation market: Applications Snapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by Applications
  • TABLE Global breakthrough therapy designation market, by Applications 2016 - 2027 (USD Million)
  • TABLE Breakthrough therapy designation market: End-User Snapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by End-User
  • TABLE Global breakthrough therapy designation market, by End-User 2016 - 2027 (USD Million)
  • TABLE Breakthrough therapy designation market: Regional snapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global breakthrough therapy designation market, by Region 2016 - 2027 (USD Million)
  • TABLE North America breakthrough therapy designation market, by Country, 2016 - 2027 (USD Million)
  • TABLE North America breakthrough therapy designation market, by Applications, 2016 - 2027 (USD Million)
  • TABLE North America breakthrough therapy designation market, by End-User, 2016 - 2027 (USD Million)
  • TABLE Europe breakthrough therapy designation market, by Country, 2016 - 2027 (USD Million)
  • TABLE Europe breakthrough therapy designation market, by Applications, 2016 - 2027 (USD Million)
  • TABLE Europe breakthrough therapy designation market, by End-User, 2016 - 2027 (USD Million)
  • TABLE Asia Pacific breakthrough therapy designation market, by Country, 2016 - 2027 (USD Million)
  • TABLE Asia Pacific breakthrough therapy designation market, by Applications, 2016 - 2027 (USD Million)
  • TABLE Asia Pacific breakthrough therapy designation market, by End-User, 2016 - 2027 (USD Million)
  • TABLE Latin America breakthrough therapy designation market, by Country, 2016 - 2027 (USD Million)
  • TABLE Latin America breakthrough therapy designation market, by Application, 2016 - 2027 (USD Million)
  • TABLE Latin America breakthrough therapy designation market, by End-User, 2016 - 2027 (USD Million)
  • TABLE Middle East and Africa breakthrough therapy designation market, by Country, 2016 - 2027 (USD Million)
  • TABLE Middle East and Africa breakthrough therapy designation market, by Application, 2016 - 2027 (USD Million)
  • TABLE Middle East and Africa breakthrough therapy designation market, by End-User, 2016 - 2027 (USD Million)

List of Figures

  • FIGURE Breakthrough therapy designation market segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2019
  • FIGURE Application segment market share analysis, 2020 & 2027
  • FIGURE Application segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Oncology market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Infectious Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rare Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Autoimmune Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Pulmonary Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Neurological Disorder market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Other Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE End-User segment market share analysis, 2020 & 2027
  • FIGURE End-User segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Hospital market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Clinic market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Research Institute market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Laboratories market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Regional segment market share analysis, 2020 & 2027
  • FIGURE Regional segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE North America breakthrough therapy designation market share and leading players, 2019
  • FIGURE Europe breakthrough therapy designation market share and leading players, 2019
  • FIGURE Asia Pacific breakthrough therapy designation market share and leading players, 2019
  • FIGURE Latin America breakthrough therapy designation market share and leading players, 2019
  • FIGURE Middle East and Africa breakthrough therapy designation market share and leading players, 2019
  • FIGURE North America market share analysis by country, 2019
  • FIGURE U.S. breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Canada breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Europe breakthrough therapy designation market share analysis by country, 2019
  • FIGURE Germany breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Spain breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Italy breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE UK breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE France breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of the Europe breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Asia Pacific breakthrough therapy designation market share analysis by country, 2019
  • FIGURE India breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE China breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Japan breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE South Korea breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Singapore breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of APACbreakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Latin America breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Latin America breakthrough therapy designation market share analysis by country, 2019
  • FIGURE Brazil breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Mexico breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Argentina breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of LATAM breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Middle East and Africa breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Middle East and Africa breakthrough therapy designation market share analysis by country, 2019
  • FIGURE Saudi Arabia breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE United Arab Emirates breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)